Staff information

John Melchior

Biomedical Scientist
Pacific Northwest National Laboratory
PO Box 999
MSIN: J4-18
Richland, WA 99352
Send Email

Diaz Ludovico I., S.M. Powell, G.M. Many, L.M. Bramer, S. Sarkar, K.G. Stratton, and T. Liu, et al. 2024. "A fast and sensitive size-exclusion chromatography method for plasma extracellular vesicle proteomic analysis." Proteomics 24, no. 16:2400025. PNNL-SA-194254. doi:10.1002/pmic.202400025
Geh E., D.K. Swertfeger, H. Sexmith, A. Heink, P. Tarapore, J.T. Melchior, and W. Davidson, et al. 2024. "A novel assay to measure low-density lipoproteins binding to proteoglycans." PLoS One 19, no. 1:Art. No. e0291632. PNNL-SA-190079. doi:10.1371/journal.pone.0291632
Tsujita M., J.T. Melchior, and S. Yokoyama. 2024. "Lipoprotein Particles in Cerebrospinal Fluid." Arteriosclerosis, Thrombosis, and Vascular Biology 44, no. 5:1042 - 1052. PNNL-SA-197441. doi:10.1161/ATVBAHA.123.318284

Gangwar A., S.S. Deodhar, S. Saldanha, O. Melander, F. Abbasi, R.W. Pearce, and T.S. Collier, et al. 2023. "Proteomic Determinants of variation in Cholesterol Efflux: Observations From the Dallas Heart Study." International Journal of Molecular Sciences 24, no. 21:Art. No. 15526. PNNL-SA-189619. doi:10.3390/ijms242115526
Merrill N.J., W. Davidson, Y. He, I. Diaz Ludovico, S. Sarkar, M.R. Berger, and J.E. McDermott, et al. 2023. "Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health." Science Advances 9, no. 35:Art. No. eadi5571. PNNL-SA-184855. doi:10.1126/sciadv.adi5571
Sarkar S., E.C. Elliott, H.R. Henry, I. Diaz Ludovico, J.T. Melchior, A. Frazer-Abel, and B.M. Webb-Robertson, et al. 2023. "Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism and immune response." Clinical Proteomics 20. PNNL-ACT-SA-10706. doi:10.1186/s12014-023-09429-6

Sarkar S., J.T. Melchior, H.R. Henry, F. Syed, R.G. Mirmira, E.S. Nakayasu, and T.O. Metz. 2022. "GDF15: a potential therapeutic target for type 1 diabetes." Expert Opinion on Therapeutic Targets 26, no. 1:57 - 67. PNNL-SA-168207. doi:10.1080/14728222.2022.2029410

Melchior J.T., S.E. Street, T. Vaisar, R. Hart, J. Jerome, Z. Kuklenyik, and N. Clouet-Foraison, et al. 2021. "Apolipoprotein A-I modulates HDL particle size in the absence of apolipoprotein A-II." Journal of Lipid Research 62. PNNL-SA-161034. doi:10.1016/j.jlr.2021.100099